Stapokibart launch price vs dupixent?

See the DrugPatentWatch profile for dupixent

What is the launch price of stapokibart, and how does it compare with Dupixent?

I don’t have any launch-price information for stapokibart in the information provided here, so I can’t state its launch price or do a direct price comparison versus Dupixent.

What’s the launch price for Dupixent (and what price should you compare against)?

Same issue: I don’t have Dupixent’s launch-price figure in the information available here, so I can’t confirm what baseline you’re using for “launch price” (U.S. list price at first approval, a specific indication, or a specific time period).

If you meant the U.S. list price (WAC), which one should we compare?

“Launch price” can mean different numbers depending on the market and pricing reference (for example, U.S. Wholesale Acquisition Cost at launch vs a later net price after rebates). If you tell me:
- country (U.S. or elsewhere),
- which Dupixent reference point you mean (at first approval or for a later label/indication),
- and whether you want WAC/list price or a net price estimate,

…I can help you line up the correct comparison format.

Can you share the stapokibart and Dupixent prices you’re using?

If you paste the price figures (or the source links you’re looking at), I can calculate the difference (absolute and percentage) and put them side-by-side in a clean comparison.